HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens.

Abstract
The cancer-testis antigens are a group of unrelated proteins aberrantly expressed in various cancers in adult somatic tissues. This aberrant expression can trigger spontaneous immune responses, a phenomenon exploited for the development of disease markers and therapeutic vaccines. However, expression levels often vary amongst patients presenting the same cancer type, and these antigens are therefore unlikely to be individually viable as diagnostic or prognostic markers. Nevertheless, patterns of antigen expression may provide correlates of specific cancer types and disease progression. Herein, we describe the development of a novel, readily customizable cancer-testis antigen microarray platform together with robust bioinformatics tools, with which to quantify anti-cancer testis antigen autoantibody profiles in patient sera. By exploiting the high affinity between autoantibodies and tumor antigens, we achieved linearity of response and an autoantibody quantitation limit in the pg/mL range-equating to a million-fold serum dilution. By using oriented attachment of folded, recombinant antigens and a polyethylene glycol microarray surface coating, we attained minimal non-specific antibody binding. Unlike other proteomics methods, which typically use lower affinity interactions between monoclonal antibodies and tumor antigens for detection, the high sensitivity and specificity realized using our autoantibody-based approach may facilitate the development of better cancer biomarkers, as well as potentially enabling pre-symptomatic diagnosis. We illustrated the usage of our platform by monitoring the response of a melanoma patient cohort to an experimental therapeutic NY-ESO-1-based cancer vaccine; inter alia, we found evidence of determinant spreading in individual patients, as well as differential CT antigen expression and epitope usage.
AuthorsNatasha Beeton-Kempen, Jessica Duarte, Aubrey Shoko, Jean-Michel Serufuri, Thomas John, Jonathan Cebon, Jonathan Blackburn
JournalInternational journal of cancer (Int J Cancer) Vol. 135 Issue 8 Pg. 1842-51 (Oct 15 2014) ISSN: 1097-0215 [Electronic] United States
PMID24604332 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 UICC.
Chemical References
  • Antibodies, Neoplasm
  • Antigens, Neoplasm
  • Antigens, Surface
  • Autoantibodies
  • CTAG2 protein, human
  • Cancer Vaccines
  • Recombinant Fusion Proteins
Topics
  • Antibodies, Neoplasm (blood)
  • Antigens, Neoplasm (biosynthesis, genetics, immunology)
  • Antigens, Surface (biosynthesis, genetics, immunology)
  • Autoantibodies (blood)
  • Cancer Vaccines (immunology, therapeutic use)
  • Cells, Cultured
  • Cloning, Molecular
  • Humans
  • Limit of Detection
  • Melanoma (blood, immunology, therapy)
  • Protein Array Analysis
  • Recombinant Fusion Proteins (biosynthesis, genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: